Neuropathy Associated With Velcade Appears Reversible, Analysis Shows
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Peripheral neuropathy associated with Millennium’s Velcade appears to be reversible in most cases, according to an analysis presented at the American Society of Hematology annual meeting Dec. 9.
You may also be interested in...
Velcade Shows Edge In Phase III Multiple Myeloma Trial; Fails In Colorectal
Millennium plans to submit its Phase III Velcade (bortezomib) confirmatory trial in multiple myeloma in the second half of 2004.
Velcade "Impressive" Efficacy Offsets Concerns Over Response As Endpoint
"Impressive" and "better than expected" efficacy results with Millennium’s multiple myeloma agent Velcade were enough to outweigh FDA’s concerns about the use of response rate as a surrogate endpoint, NDA review documents indicate.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011